1
|
Khelef K, Maubec E, Jeudy G, Bonniaud B, Pham-Ledard A, Herms F, Aubin F, Beneton N, Dinulescu M, Jannic A, Duval-Modeste A, Archier E, Berthin C, Grange F, Arnault J, Heidelberger V, Moncourier M, Mansard S, Brunet-Possenti F, Triller R, Pracht M, Dumas M, Lauche O, Mortier L, Bedane C, Dalac Rat S. Duration of treatment with cemiplimab in advanced cutaneous squamous cell carcinoma in complete response: Real-life study. J Eur Acad Dermatol Venereol 2024; 38:e71-e73. [PMID: 37595320 DOI: 10.1111/jdv.19435] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2023] [Accepted: 08/11/2023] [Indexed: 08/20/2023]
Affiliation(s)
- K Khelef
- Service de Dermatologie, Centre Hospitalier Universitaire (CHU), Dijon, France
| | - E Maubec
- Service de Dermatologie, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (APHP), Bobigny, France
- Campus de Bobigny-Université Sorbonne Paris Nord, Bobigny, France
- UMR 1124, Campus Saint Germain des Prés, Paris, France
| | - G Jeudy
- Service de Dermatologie, Centre Hospitalier Universitaire (CHU), Dijon, France
| | - B Bonniaud
- Service de Dermatologie, Centre Hospitalier Universitaire (CHU), Dijon, France
| | - A Pham-Ledard
- Service de Dermatologie, CHU de Bordeaux, Bordeaux, France
- Université de Bordeaux, Bordeaux, France
| | - F Herms
- Service de Dermatologie, Hôpital Saint-Louis, APHP, Paris, France
| | - F Aubin
- Service de Dermatologie, INSERM 1098, CHU de Besançon de Franche Comté, Besançon, France
- Université de Bourgogne-Franche-Comté, Besançon, France
| | - N Beneton
- Service de Dermatologie, CH du Mans, Le Mans, France
| | - M Dinulescu
- Service de Dermatologie, Hôpital Pontchaillou, Rennes, France
| | - A Jannic
- Service de Dermatologie, Hôpital Henri-Mondor, APHP, Créteil, France
| | - A Duval-Modeste
- Service de Dermatologie, Hôpital Charles-Nicolle, Rouen, France
| | - E Archier
- Service de Dermatologie, Hôpital Saint-Joseph, Marseille, France
| | - C Berthin
- Service de Dermatologie, CHU d'Angers, Angers, France
| | - F Grange
- Service de Dermatologie, CHU de Reims, Reims, France
| | - J Arnault
- Service de Dermatologie, CHU Amiens-Picardie, Amiens, France
| | - V Heidelberger
- Service de Dermatologie, CH Robert-Ballanger, Aulnay-sous-Bois, France
| | - M Moncourier
- Service de Dermatologie, CHU de Grenoble-Alpes, Grenoble, France
| | - S Mansard
- Service de Dermatologie, CHU de Clermont-Ferrand, Clermont-Ferrand, France
| | | | - R Triller
- Service de Dermatologie, Institut Franco-Britannique, Levallois-Perret, France
| | - M Pracht
- Groupe Hospitalier de St-Malo, Saint-Malo, France
| | - M Dumas
- Service de Dermatologie, CH René-Dubos, Pontoise, France
| | - O Lauche
- Clinique Clémentville, Montpellier, France
| | - L Mortier
- Service de Dermatologie, CHU de Lille, Lille, France
- INSERM U 1189, Université de Lille, Lille, France
| | - C Bedane
- Service de Dermatologie, Centre Hospitalier Universitaire (CHU), Dijon, France
| | - S Dalac Rat
- Service de Dermatologie, Centre Hospitalier Universitaire (CHU), Dijon, France
| |
Collapse
|
2
|
Hébert V, Bastos S, Drenovska K, Meijer J, Ingen-Housz-Oro S, Bedane C, Lunardon L, Debarbieux S, Jedlickova H, Caux F, Chaby G, D'Incan M, Feliciani C, Boulard C, Schumacher N, Schmidt E, Roussel A, Richard MA, Gottlieb J, Ferranti V, Guérin O, Bénichou J, Joly P. International multicentre observational study to assess the efficacy and safety of a 0·5 mg kg -1 per day starting dose of oral corticosteroids to treat bullous pemphigoid. Br J Dermatol 2021; 185:1232-1239. [PMID: 34173243 DOI: 10.1111/bjd.20593] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/17/2021] [Indexed: 11/28/2022]
Abstract
BACKGROUND European guidelines propose a 0·5 mg kg-1 per day dose of oral prednisone as initial treatment for bullous pemphigoid (BP). We assessed the safety and efficacy of this regimen depending on BP extent and general condition of the patients. METHODS In a prospective international study, we consecutively included all patients diagnosed with BP. Patients received a 0·5 mg kg-1 per day dose of prednisone, which was then gradually tapered 15 days after disease control, with the aim of stopping prednisone or maintaining minimal treatment (0·1 mg kg-1 per day) within 6 months after the start of treatment. The two coprimary endpoints were control of disease activity at day 21 and 1-year overall survival. Disease severity was assessed according to the Bullous Pemphigoid Disease Area Index (BPDAI) score. RESULTS In total, 198 patients were included between 2015 and 2017. The final analysis comprised 190 patients with a mean age of 80·9 (SD 9·1) years. Control of disease activity was achieved at day 21 in 119 patients [62·6%, 95% confidence interval (CI) 55·3-69.5]; 18 of 24 patients (75%, 95% CI 53·3-90·2), 75 of 110 patients (68·8%, 95% CI 59·2-77·3) and 26 of 56 patients (46.4%, 95% CI 33·0-60·3) had mild, moderate and severe BP, respectively (P = 0·0218). A total of 30 patients died during the study. The overall Kaplan-Meier 1-year survival was 82·6% (95% CI 76·3-87·4) corresponding to 90·9%, 83·0% and 80·0% rates in patients with mild, moderate and severe BP, respectively (P = 0·5). Thresholds of 49 points for BPDAI score and 70 points for Karnofsky score yielded maximal Youden index values with respect to disease control at day 21 and 1-year survival, respectively. CONCLUSIONS A 0·5 mg kg-1 per day dose of prednisone is a valuable therapeutic option in patients with mild or moderate BP whose general condition allows them to be autonomous.
Collapse
Affiliation(s)
- V Hébert
- Department of Dermatology, Rouen University Hospital, Center for Autoimmune Bullous Diseases, and INSERM U1234, Normandie University, Rouen, France
| | - S Bastos
- Department of Dermatology, Rouen University Hospital, Center for Autoimmune Bullous Diseases, and INSERM U1234, Normandie University, Rouen, France
| | - K Drenovska
- Department of Dermatology, Medical University of Sofia, Sofia, Bulgaria
| | - J Meijer
- Center for Blistering Diseases, Department of Dermatology, University Medical Center Groningen, Groningen, the Netherlands
| | - S Ingen-Housz-Oro
- Department of Dermatology, Henri Mondor University Hospital, (AP-HP), Creteil, France
| | - C Bedane
- Department of Dermatology, Limoges University Hospital, Limoges, France
| | - L Lunardon
- Università degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - S Debarbieux
- Department of Dermatology, Hospices Civils de Lyon, Lyon, France
| | - H Jedlickova
- Department of Dermatology, St. Anne's Faculty Hospital, Brno, Czech Republic
| | - F Caux
- Department of Dermatology, Avicenne Hospital, University Paris 13, Bobigny, France
| | - G Chaby
- Department of Dermatology, Amiens University Hospital, Amiens, France
| | - M D'Incan
- Department of Dermatology, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
| | - C Feliciani
- Section of Dermatology, Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy
| | - C Boulard
- Department of Dermatology, Monod General Hospital, le Havre, France
| | - N Schumacher
- Department of Dermatology, University of Lübeck, Lübeck, Germany
| | - E Schmidt
- Department of Dermatology, University of Lübeck, Lübeck, Germany.,Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany
| | - A Roussel
- Department of Dermatology, Orleans Hospital, Orléans, France
| | - M A Richard
- Department of Dermatology, Hôpital la Timone, Assistance Publique des Hôpitaux de Marseille, Marseille, France
| | - J Gottlieb
- Department of Dermatology, Saint Louis Hospital, (AP-HP), Paris, France
| | - V Ferranti
- Department of Biostatistics, Rouen University Hospital, Rouen, France
| | - O Guérin
- Department of Biostatistics, Rouen University Hospital, Rouen, France
| | - J Bénichou
- Department of Biostatistics, Rouen University Hospital, Rouen, France
| | - P Joly
- Department of Dermatology, Rouen University Hospital, Center for Autoimmune Bullous Diseases, and INSERM U1234, Normandie University, Rouen, France
| | | |
Collapse
|
3
|
Fredeau L, Hober C, Pham-Ledard A, Boubaya M, Herms F, Celerier P, Aubin F, Beneton N, Dinulescu M, Jannic A, Meyer N, Duval Modeste AB, Cesaire L, Neidhardt EM, Archier E, Dreno B, Lesage C, Berthin C, Kramkimel N, Grange F, De Quatrebarbes J, Stoebner P, Poulalhon N, Arnault J, Abed S, Bonniaud B, Darras S, Heidelberger V, Devaux S, Moncourier M, Misery L, Mansard S, Etienne M, Brunet-Possenti F, Jacobzone C, Lesbazeilles R, Skowron F, Sanchez J, Catala S, Samimi M, Tazi Y, Spaeth D, Gaudy-Marqueste C, Collard O, Triller R, Pracht M, Dumas M, Peuvrel L, Combe P, Lauche O, Guillet P, Reguerre Y, Kupfer-Bessaguet I, Solub D, Schoeffler A, Bedane C, Dalac S, Mortier L, Maubec E. Cémiplimab et carcinomes épidermoïdes cutanés localement évolués ou métastatiques : premières données de vie réelle. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
4
|
Mio Bertolo E, Assikar S, Hazard M, Matei I, Bedane C. Photothérapie dynamique en lumière naturelle associée au mébutate d’ingénol dans le traitement des kératoses actiniques : étude pilote comparative. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.217] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
5
|
Khammari A, Dinulescu M, Nguyen JM, Cassecuel J, Maillard H, Le Duff F, Machet L, Beylot-Barry M, Legoupil D, Wierzbicka-Hainaut E, Bedane C, Leccia MT, Debarbieux S, Meyer N, Monestier S, Bens G, Denis M, Vourch M, Bossard C, Vergier B, Dréno B. L’efficacité de l’imiquimod dans la prise en charge du mélanome de Dubreuilh in situ (lentigo malin). Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
6
|
Marescassier H, Dousset L, Hainaut E, Bedane C, Vaillant L, Celerier P, Beylot-Barry M, Masson Regnault M. Facteurs prédictifs de non réponse au vismodégib dans les carcinomes basocellulaires localement avancés. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
7
|
Flament J, Jouen F, Tancrède-Bohin E, Oro S, Picard-Dahan C, Konstantinou M, Dereure O, Seta V, Quereux G, Prost C, Bedane C, Debarbieux S, Bourgault-Villada I, Delaporte E, Lacour JP, Richard MA, Pham-Ledard A, D’Incan M, Abasq C, Duvert-Lehembre S, Lombart F, Dupuy A, Hainaut E, Dompmartin A, Leccia MT, Vabres P, Alcaraz I, Michel C, Lagrange B, Litrowski N, Estève E, Machet L, Martin L, Del Giudice P, Fenot M, Belmondo T, Morin F, Tressières B, Joly P, Cordel N. Étude du taux d’anticorps anti-BPAG2, mesuré par technique ELISA, comme biomarqueur des complications gravidiques au cours de la pemphigoïde de la grossesse. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
8
|
Chen D, Odueyungbo A, Csinady E, Gearhart L, Lehane P, Cheu M, Maho‐Vaillant M, Prost‐Squarcioni C, Hebert V, Houivet E, Calbo S, Caillot F, Golinski M, Labeille B, Picard‐Dahan C, Paul C, Richard M, Bouaziz J, Duvert‐Lehembre S, Bernard P, Caux F, Alexandre M, Ingen‐Housz‐Oro S, Vabres P, Delaporte E, Quereux G, Dupuy A, Debarbieux S, Avenel‐Audran M, D'Incan M, Bedane C, Bénéton N, Jullien D, Dupin N, Misery L, Machet L, Beylot‐Barry M, Dereure O, Sassolas B, Benichou J, Musette P, Joly P. Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect. Br J Dermatol 2020; 182:1111-1119. [PMID: 31487383 PMCID: PMC7317434 DOI: 10.1111/bjd.18482] [Citation(s) in RCA: 46] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/29/2019] [Indexed: 12/11/2022]
Abstract
BACKGROUND Corticosteroids (CS) with or without adjuvant immunosuppressant agents are standard treatment for pemphigus vulgaris (PV). The efficacy of adjuvant therapies in minimizing steroid-related adverse events (AEs) is unproven. OBJECTIVES To utilize data collected in a French investigator-initiated, phase III, open-label, randomized controlled trial to demonstrate the efficacy and safety of rituximab and seek approval for its use in PV. METHODS This was an independently conducted post hoc analysis of the moderate-to-severe PV subset enrolled in the Ritux 3 study. Patients were randomized to rituximab plus 0·5 or 1·0 mg kg-1 per day prednisone tapered over 3 or 6 months, or 1·0 or 1·5 mg kg-1 per day prednisone alone tapered over 12 or 18 months, respectively (according to disease severity). The primary end point was complete remission at month 24 without CS (CRoff) for ≥ 2 months, and 24-month efficacy and safety results were also reported. RESULTS At month 24, 34 of 38 patients (90%) on rituximab plus prednisone achieved CRoff ≥ 2 months vs. 10 of 36 patients (28%) on prednisone alone. Median total cumulative prednisone dose was 5800 mg in the rituximab plus prednisone arm vs. 20 520 mg for prednisone alone. Eight of 36 patients (22%) who received prednisone alone withdrew from treatment owing to AEs; one rituximab-plus-prednisone patient withdrew due to pregnancy. Overall, 24 of 36 patients (67%) on prednisone alone experienced a grade 3/4 CS-related AE vs. 13 of 38 patients (34%) on rituximab plus prednisone. CONCLUSIONS In patients with moderate-to-severe PV, rituximab plus short-term prednisone was more effective than prednisone alone. Patients treated with rituximab had less CS exposure and were less likely to experience severe or life-threatening CS-related AEs. What's already known about this topic? Pemphigus vulgaris (PV) is the most common type of pemphigus. Corticosteroids, a standard first-line treatment for PV, have significant side-effects. Although their effects are unproven, adjuvant corticosteroid-sparing agents are routinely used to minimize steroid exposure and corticosteroid-related side-effects. There is evidence that the anti-CD20 antibody rituximab is effective in the treatment of patients with severe recalcitrant pemphigus and in patients with newly diagnosed pemphigus. What does this study add? This study provides a more detailed analysis of patients with PV enrolled in an investigator-initiated trial. Rituximab plus prednisone had a steroid-sparing effect and more patients achieved complete remission off prednisone. Fewer patients experienced grade 3 or grade 4 steroid-related adverse events than those on prednisone alone. This collaboration between academia and industry, utilizing independent post hoc analyses, led to regulatory authority approvals of rituximab in moderate-to-severe PV.
Collapse
|
9
|
Bastos S, Hebert V, Vassileva S, Patsatsi A, Meijer J, Quéreux G, Bedane C, Prost-Squarcioni C, Debardieux S, Oro S, Chaby G, D’Incan M, Litrowski N, Boulard C, Lunardon L, Kiritsi D, Jedlickova H, Feliciani C, Roussel A, Kottler D, Plantin P, Richard MA, Friedrichsen L, Abasq C, Duvert Lehembre S, Gottlieb J, Zebrowska A, Hofmann S, Joly P. Efficacité et tolérance de la prednisone à 0,5 mg/kg/j en traitement initial de la pemphigoïde bulleuse. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.038] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
10
|
Bourgaux M, Marcaillou M, Matei I, Delaumenie S, Prud'homme R, Souyri N, Bedane C. Man of stone: A case of a chronic actinic dermatitis mimicking a cutis verticis gyrata. J Eur Acad Dermatol Venereol 2019; 34:e129-e130. [PMID: 31715028 DOI: 10.1111/jdv.16068] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- M Bourgaux
- Dermatology Department, CHU Dupuytren, 2 av. Martin Luther King, Limoges, F-87000, France
| | - M Marcaillou
- Dermatology Department, CHU Dupuytren, 2 av. Martin Luther King, Limoges, F-87000, France
| | - I Matei
- Dermatology Department, CHU Dupuytren, 2 av. Martin Luther King, Limoges, F-87000, France
| | - S Delaumenie
- Dermatology Department, CHU Dupuytren, 2 av. Martin Luther King, Limoges, F-87000, France
| | - R Prud'homme
- Dermatology Department, CHU Dupuytren, 2 av. Martin Luther King, Limoges, F-87000, France
| | - N Souyri
- Dermatology Department, CHU Dupuytren, 2 av. Martin Luther King, Limoges, F-87000, France
| | - C Bedane
- Dermatology Department, CHU Dupuytren, 2 av. Martin Luther King, Limoges, F-87000, France
| |
Collapse
|
11
|
Mignard C, Maho-Vaillant M, Prost-Squarcioni C, Calbo S, Golinski ML, Labeille B, Picard-Dahan C, Konstantinou M, Richard MA, Bouaziz J, Duvert-Lehembre S, Bernard P, Caux F, Alexandre M, Oro S, Vabres P, Quereux G, Dupuy A, Debarbieux S, Martin L, D’Incan M, Bedane C, Bénéton N, Jullien D, Dupin N, Misery L, Machet L, Beylot-Barry M, Dereure O, Sassolas B, Hébert V, Joly P. Facteurs pronostiques de rechute à long terme chez les patients atteints de pemphigus traités par rituximab en première ligne. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
12
|
Saiag P, Robert C, Grob J, Mortier L, Dereure O, Lebbe C, Mansard S, Grange F, Neidhardt EM, Lesimple T, Machet L, Bedane C, Maillard H, Dalac-Rat S, Nardin C, Szenik A, Denden A, Dutriaux C. Factors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600-mutant melanoma: An open label, non randomized study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz255.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
13
|
Dutriaux C, Robert C, Grob J, Mortier L, Dereure O, Lebbe C, Mansard S, Grange F, Neidhardt EM, Lesimple T, Machet L, Bedane C, Maillard H, Dalac-Rat S, Nardin C, Szenik A, Denden A, Saiag P. An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: A subgroup analysis of patients with brain metastasis. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz255.021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
14
|
Jelti L, Prost-Squarcioni C, Ingen-Housz-Oro S, Caux F, Bernard P, Bedane C, Alexandre M, Dereure O, Quereux G, Le Bidre E, Plée J, Picard-Dahan C, Le Roux-Villet C, Duvert-Lehembre S, Richard MA, Delaporte E, Debarbieux S, Jullien D, D'Incan M, Konstantinou MP, Bouaziz JD, Tancrède-Bohin E, Doutre MS, Bourgault Villada I, Cordel N, Sassolas B, Viguier MA, Mellottée B, Jouen F, Hebert V, Joly P. [Update of the French recommendations for the management of pemphigus]. Ann Dermatol Venereol 2019; 146:279-286. [PMID: 30929874 DOI: 10.1016/j.annder.2019.01.018] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2018] [Revised: 11/24/2018] [Accepted: 01/23/2019] [Indexed: 01/29/2023]
Affiliation(s)
- L Jelti
- Service de dermatologie, Inserm U1234, université de Normandie, CHU de Rouen, 1 rue de Germont, 76000 Rouen, France.
| | - C Prost-Squarcioni
- Service de dermatologie, université Paris 13, hôpital Avicenne, AP-HP, 93000 Bobigny, France
| | - S Ingen-Housz-Oro
- Service de dermatologie, hôpital Henri-Mondor, AP-HP, 94000 Créteil, France
| | - F Caux
- Service de dermatologie, université Paris 13, hôpital Avicenne, AP-HP, 93000 Bobigny, France
| | - P Bernard
- Service de dermatologie, hôpital Robert-Debré, CHU de Reims, 51092 Reims, France
| | - C Bedane
- Service de dermatologie, hôpital Dupuytren, 87042 Limoges, France
| | - M Alexandre
- Service de dermatologie, université Paris 13, hôpital Avicenne, AP-HP, 93000 Bobigny, France
| | - O Dereure
- Service de dermatologie, Inserm U1058, université de Montpellier, hôpital St-Eloi, 34295 Montpellier, France
| | - G Quereux
- Service de dermatologie, CHU Hôtel-Dieu, 44093 Nantes, France
| | - E Le Bidre
- Service de dermatologie, hôpital Trousseau, CHRU de Tours, 37044 Tours, France
| | - J Plée
- Service de dermatologie, hôpital Robert-Debré, CHU de Reims, 51092 Reims, France
| | - C Picard-Dahan
- Service de dermatologie, hôpital Bichat-Claude-Bernard, AP-HP, 75018 Paris, France
| | - C Le Roux-Villet
- Service de dermatologie, université Paris 13, hôpital Avicenne, AP-HP, 93000 Bobigny, France
| | - S Duvert-Lehembre
- Service de dermatologie, hôpital Claude-Huriez, CHRU de Lille, 59037 Lille, France
| | - M-A Richard
- EA3279 : CEReSS-centre d'étude et de recherche sur les services de santé et la qualité de vie, service de dermatologie, université Aix-Marseille, hôpital de La Timone, Assistance publique-Hôpitaux de Marseille, 13385 Marseille, France
| | - E Delaporte
- Service de dermatologie, université Aix-Marseille, hôpital Nord, Assistance publique-Hôpitaux de Marseille, 13385 Marseille, France
| | - S Debarbieux
- Service de dermatologie, hôpital Edouard-Herriot, hospices civils de Lyon, 69437 Lyon, France
| | - D Jullien
- Service de dermatologie, hôpital Edouard-Herriot, hospices civils de Lyon, 69437 Lyon, France
| | - M D'Incan
- Service de dermatologie, CHU Estaing, 63000 Clermont-Ferrand, France
| | - M-P Konstantinou
- Service de dermatologie, hôpital Larrey, CHU de Toulouse, 31059 Toulouse, France
| | - J-D Bouaziz
- Service de dermatologie, hôpital Saint-Louis, AP-HP, 75010 Paris, France
| | - E Tancrède-Bohin
- Service de dermatologie, hôpital Saint-Louis, AP-HP, 75010 Paris, France
| | - M-S Doutre
- Service de dermatologie, hôpital Saint-André, CHU de Bordeaux, 33000 Bordeaux, France
| | - I Bourgault Villada
- Service de dermatologie, hôpital Ambroise-Paré, AP-HP, 92100 Boulogne-Billancourt, France
| | - N Cordel
- Service de dermatologie, Inserm U1234, université de Normandie, CHU de Rouen, 1 rue de Germont, 76000 Rouen, France; Unité de dermatologie-immunologie clinique, CHU de Guadeloupe, 97159 Pointe-à-Pitre cedex, Guadeloupe
| | - B Sassolas
- Service de médecine interne et pneumologie, hôpital de la Cavale-Blanche, CHRU de Brest, 29609 Brest, France
| | - M-A Viguier
- Service de dermatologie, hôpital Robert-Debré, CHU de Reims, 51092 Reims, France
| | - B Mellottée
- Service de dermatologie, université Paris 13, hôpital Avicenne, AP-HP, 93000 Bobigny, France
| | - F Jouen
- Inserm U1234, laboratoire d'immunologie, université de Normandie, CHU de Rouen, 76000 Rouen, France
| | - V Hebert
- Service de dermatologie, Inserm U1234, université de Normandie, CHU de Rouen, 1 rue de Germont, 76000 Rouen, France
| | - P Joly
- Service de dermatologie, Inserm U1234, université de Normandie, CHU de Rouen, 1 rue de Germont, 76000 Rouen, France
| | -
- Service de dermatologie, Inserm U1234, université de Normandie, CHU de Rouen, 1 rue de Germont, 76000 Rouen, France; Service de dermatologie, université Paris 13, hôpital Avicenne, AP-HP, 93000 Bobigny, France; Service de dermatologie, hôpital Henri-Mondor, AP-HP, 94000 Créteil, France; Service de dermatologie, hôpital Robert-Debré, CHU de Reims, 51092 Reims, France; Service de dermatologie, hôpital Dupuytren, 87042 Limoges, France; Service de dermatologie, Inserm U1058, université de Montpellier, hôpital St-Eloi, 34295 Montpellier, France; Service de dermatologie, CHU Hôtel-Dieu, 44093 Nantes, France; Service de dermatologie, hôpital Trousseau, CHRU de Tours, 37044 Tours, France; Service de dermatologie, hôpital Bichat-Claude-Bernard, AP-HP, 75018 Paris, France; Service de dermatologie, hôpital Claude-Huriez, CHRU de Lille, 59037 Lille, France; EA3279 : CEReSS-centre d'étude et de recherche sur les services de santé et la qualité de vie, service de dermatologie, université Aix-Marseille, hôpital de La Timone, Assistance publique-Hôpitaux de Marseille, 13385 Marseille, France; Service de dermatologie, université Aix-Marseille, hôpital Nord, Assistance publique-Hôpitaux de Marseille, 13385 Marseille, France; Service de dermatologie, hôpital Edouard-Herriot, hospices civils de Lyon, 69437 Lyon, France; Service de dermatologie, CHU Estaing, 63000 Clermont-Ferrand, France; Service de dermatologie, hôpital Larrey, CHU de Toulouse, 31059 Toulouse, France; Service de dermatologie, hôpital Saint-Louis, AP-HP, 75010 Paris, France; Service de dermatologie, hôpital Saint-André, CHU de Bordeaux, 33000 Bordeaux, France; Service de dermatologie, hôpital Ambroise-Paré, AP-HP, 92100 Boulogne-Billancourt, France; Unité de dermatologie-immunologie clinique, CHU de Guadeloupe, 97159 Pointe-à-Pitre cedex, Guadeloupe; Service de médecine interne et pneumologie, hôpital de la Cavale-Blanche, CHRU de Brest, 29609 Brest, France; Inserm U1234, laboratoire d'immunologie, université de Normandie, CHU de Rouen, 76000 Rouen, France
| | -
- Service de dermatologie, Inserm U1234, université de Normandie, CHU de Rouen, 1 rue de Germont, 76000 Rouen, France; Service de dermatologie, université Paris 13, hôpital Avicenne, AP-HP, 93000 Bobigny, France; Service de dermatologie, hôpital Henri-Mondor, AP-HP, 94000 Créteil, France; Service de dermatologie, hôpital Robert-Debré, CHU de Reims, 51092 Reims, France; Service de dermatologie, hôpital Dupuytren, 87042 Limoges, France; Service de dermatologie, Inserm U1058, université de Montpellier, hôpital St-Eloi, 34295 Montpellier, France; Service de dermatologie, CHU Hôtel-Dieu, 44093 Nantes, France; Service de dermatologie, hôpital Trousseau, CHRU de Tours, 37044 Tours, France; Service de dermatologie, hôpital Bichat-Claude-Bernard, AP-HP, 75018 Paris, France; Service de dermatologie, hôpital Claude-Huriez, CHRU de Lille, 59037 Lille, France; EA3279 : CEReSS-centre d'étude et de recherche sur les services de santé et la qualité de vie, service de dermatologie, université Aix-Marseille, hôpital de La Timone, Assistance publique-Hôpitaux de Marseille, 13385 Marseille, France; Service de dermatologie, université Aix-Marseille, hôpital Nord, Assistance publique-Hôpitaux de Marseille, 13385 Marseille, France; Service de dermatologie, hôpital Edouard-Herriot, hospices civils de Lyon, 69437 Lyon, France; Service de dermatologie, CHU Estaing, 63000 Clermont-Ferrand, France; Service de dermatologie, hôpital Larrey, CHU de Toulouse, 31059 Toulouse, France; Service de dermatologie, hôpital Saint-Louis, AP-HP, 75010 Paris, France; Service de dermatologie, hôpital Saint-André, CHU de Bordeaux, 33000 Bordeaux, France; Service de dermatologie, hôpital Ambroise-Paré, AP-HP, 92100 Boulogne-Billancourt, France; Unité de dermatologie-immunologie clinique, CHU de Guadeloupe, 97159 Pointe-à-Pitre cedex, Guadeloupe; Service de médecine interne et pneumologie, hôpital de la Cavale-Blanche, CHRU de Brest, 29609 Brest, France; Inserm U1234, laboratoire d'immunologie, université de Normandie, CHU de Rouen, 76000 Rouen, France
| |
Collapse
|
15
|
Hebert V, Vermeulin T, Prost-Squarcioni C, Picard-Dahan C, Duvert-Lehembre S, Bruno L, Marie-Aleth R, Bernard P, Dupuy A, Bouaziz JD, Oro S, Dalac-Rat S, Delaporte E, Avenel-Audran M, Sassolas B, Alexandre M, Caux F, D’Incan M, Bedane C, Quereux G, Machet L, Dereure O, Skowron F, Franck N, Beylot-Barry M, Doutre MS, Debarbieux S, Jullien D, Misery L, Musette P, Paul C, Vabres P, Bénéton N, Dupin N, Houivet E, Joly P. Comparaison des coûts de santé du traitement de première ligne par rituximab par rapport à la corticothérapie standard chez les patients pemphigus nouvellement diagnostiqués. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
16
|
Delaumenie S, Assikar S, Prud’homme R, Matei I, Couture M, Souyri N, Couraud A, Bedane C. Efficacité et tolérance du méthotrexate dans la pemphigoïde bulleuse en Limousin. Étude rétrospective de 52 patients. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
17
|
Pittoni J, Bedane C, Diabate A, Couture M, Prud’homme R, Matei I, Assikar S, Audevard D. Efficacité d’un anti-IL6 dans deux cas de pemphigoïde bulleuse sévère. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
18
|
Douard P, Prud’Homme R, Assikar S, Matei I, Bourgaux M, Jaccard A, Bedane C. Association myélome et dermatose à IgA intra-épidermique. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
19
|
Marcaillou M, Bourgaux M, Prud’homme R, Matei I, Assikar S, Bedane C. Efficacité de l’imatinib (Glivec®) sur deux mélanomes muqueux métastatiques mutés KIT. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.517] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
20
|
|
21
|
Masmoudi W, Hebert V, Quéreux G, Bedane C, Prost-Squarcioni C, Debarbieux S, Oro S, Chaby G, D’incan M, Litrowski N, Boulard C, Roussel A, Kottler D, Abasq C, Richard MA, Duvert-Lehembre S, Gottlieb J, Plantin P, Joly P. Calcul des valeurs seuils du score BPDAI (Bullous Pemphigoid Disease Area Index) définissant les formes légères, modérées et sévères de la pemphigoïde bulleuse. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
22
|
Jelti L, Cordel N, Gillibert A, Lacour JP, Uthurriague C, Doutre MS, Delaporte E, Duvert-Lehembre S, Quereux G, Dupuy A, Adamski H, Bedane C, Misery L, Abasq Thomas C, Fleuret C, Bernard P, Chaby G, D’incan M, Verneuil L, Litrowski N, Joly P. Mortalité du pemphigus et facteurs pronostiques, incluant les traitements initialement proposés. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
23
|
Naqi A, Bedane C, Souyri N, Diabaté A. Photosensibilité persistante au verteporfin. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
24
|
Richard MA, Lacour JP, Konstantinou MP, Ruer-Mulard M, Bedane C, Misery L, Martin L, Aubron-Olivier C, Chalmers R. Évaluation de l’efficacité du secukinumab à l’aide de l’indice simplifié du Psoriasis : résultat d’une étude clinique prospective. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.427] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
25
|
Douard P, Assikar S, Matei I, Prud’homme R, Audevar D, Bedane C. Pemphigus vulgaire et réactivation virale. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
26
|
Delaumenie S, Assikar S, Matei I, Souyri N, Audevard D, Bedane C. Psoriasis et pemphigoïde bulleuse. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.292] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
27
|
Jelti L, Le Bourhis-Zaimi M, Lacour JP, Uthurriague C, Doutre MS, Delaporte E, Duvert-Lehembre S, Quereux G, Dupuy A, Adamski H, Bedane C, Misery L, Abasq Thomas C, Fleuret C, Bernard P, Chaby G, D’incan M, Verneuil L, Litrowski N, Joly P. Incidence et mortalité du pemphigus en France. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.147] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
28
|
Woillard JB, Maffioletti PF, Assikar S, Monchaud C, Marquet P, Couraud A, Matei I, Bedane C. Intérêt du suivi thérapeutique pharmacologique de l’acide mycophénolique chez des patients traités pour pemphigoïde cicatricielle. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.299] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
29
|
Couture M, Laumonier J, Audevard D, Assikar S, Bordes S, Closs B, Bedane C. L’IL6 est significativement augmentée dans les formes sévères de pemphigoïde bulleuse. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.294] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
30
|
Bonigen J, Raynaud-Donzel C, Hureaux J, Kramkimel N, Blom A, Jeudy G, Breton AL, Hubiche T, Bedane C, Legoupil D, Pham-Ledard A, Charles J, Pérol M, Gérard E, Combemale P, Bonnet D, Sigal ML, Mahé E. Anti-PD1-induced psoriasis: a study of 21 patients. J Eur Acad Dermatol Venereol 2016; 31:e254-e257. [PMID: 27739129 DOI: 10.1111/jdv.14011] [Citation(s) in RCA: 126] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- J Bonigen
- Service de Dermatologie, Hôpital Victor Dupouy, Argenteuil, France
| | - C Raynaud-Donzel
- Service de Pneumologie, Hôpital Victor Dupouy, Argenteuil, France
| | - J Hureaux
- Service de Pneumologie, Centre Hospitalier Universitaire, Angers, France
| | - N Kramkimel
- Service de Dermatologie, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - A Blom
- Service de Dermatologie Générale et Oncologique, Centre Hospitalier Universitaire Ambroise Paré, Assistance Publique-Hôpitaux de Paris, Boulogne-Billancourt, France
| | - G Jeudy
- Service de Dermatologie, Centre Hospitalier Universitaire François Mitterrand, Dijon, France
| | - A-L Breton
- Service de Dermatologie, Centre Hospitalier Universitaire de Lyon Sud, Lyon, France
| | - T Hubiche
- Unité de Dermatologie Infectiologie, Centre Hospitalier Intercommunal de Fréjus/Saint-Raphaël, Fréjus, France
| | - C Bedane
- Service de Dermatologie, Centre Hospitalier Universitaire de Limoges, Limoges, France
| | - D Legoupil
- Service de Dermatologie, Centre Hospitalier Régional et Universitaire de Brest, Brest, France
| | - A Pham-Ledard
- Service de Dermatologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
| | - J Charles
- Service de Dermatologie, CHU Grenoble, Grenoble, France
| | - M Pérol
- Département de Cancérologie Médicale, Centre Léon Bérard, Lyon, France
| | - E Gérard
- Service de Dermatologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
| | - P Combemale
- Unité d'Onco-Dermatolgie, Centre Léon Bérard, Lyon, France
| | - D Bonnet
- Service de Dermatologie Générale et Oncologique, Centre Hospitalier Universitaire Ambroise Paré, Assistance Publique-Hôpitaux de Paris, Boulogne-Billancourt, France
| | - M-L Sigal
- Service de Dermatologie, Hôpital Victor Dupouy, Argenteuil, France
| | - E Mahé
- Service de Dermatologie, Hôpital Victor Dupouy, Argenteuil, France
| | | |
Collapse
|
31
|
Rigot E, Cypierre A, Liozon E, Bézananary H, Gondran G, Ly K, Fauchais A, Bedane C, Palat S. Prise en charge de la douleur engendrée par les ulcérations digitales dans la sclérodermie : résultats d’une enquête de pratique. Rev Med Interne 2016. [DOI: 10.1016/j.revmed.2016.04.233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
32
|
Boulard C, Duvert Lehembre S, Picard‐Dahan C, Kern J, Zambruno G, Feliciani C, Marinovic B, Vabres P, Borradori L, Prost‐Squarcioni C, Labeille B, Richard M, Ingen‐Housz‐Oro S, Houivet E, Werth V, Murrell D, Hertl M, Benichou J, Joly P, Hofmann S, Camaioni B, Didona B, Fania L, Della Torre R, Caux F, Alexandre M, Paul C, Bulai Livideanu C, Delaporte E, Dupuy A, Avenel‐Audran M, Schmidt E, Schumacher N, Bagot M, Tancrede‐Bohin E, Bouaziz J, D'Incan M, Quereux G, Skowron F, Beylot‐Barry M, Doutre M, Bedane C, Bernard P, Machet L, Jullien ., Debarbieux S, Dereure O, Hünefeld C, Schanz S, Franck N, Maillard H, Misery L, Sassolas B, Abasq C, Bouyeure A, Lagoutte P, Ferranti V. Calculation of cut‐off values based on the Autoimmune Bullous Skin Disorder Intensity Score (
ABSIS
) and Pemphigus Disease Area Index (
PDAI
) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus. Br J Dermatol 2016; 175:142-9. [DOI: 10.1111/bjd.14405] [Citation(s) in RCA: 54] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/14/2016] [Indexed: 11/27/2022]
Affiliation(s)
- C. Boulard
- Department of Dermatology Rouen University Hospital, and INSERM U905 Institute for Research and Innovation in Biomedicine University of Rouen Rouen France
| | - S. Duvert Lehembre
- Department of Dermatology Rouen University Hospital, and INSERM U905 Institute for Research and Innovation in Biomedicine University of Rouen Rouen France
| | - C. Picard‐Dahan
- Department of Dermatology Bichat University Hospital AP‐HP Paris France
| | - J.S. Kern
- Department of Dermatology Medical Center University of Freiburg Freiburg Germany
| | - G. Zambruno
- Laboratory of Molecular and Cell Biology Istituto Dermopatico dell'Immacolata IRCCS Via Monti di Creta 104 00167 Roma Italy
| | - C. Feliciani
- Policlinico Gemelli – Università Cattolica del ‘Sacro Cuore’ Largo Gemelli 8 00168 Roma Italy
| | - B. Marinovic
- University Hospital Center Zagreb Department of Dermatology and Venereology Salata 4 10000 Zagreb Croatia
| | - P. Vabres
- Department of Dermatology Dijon University Hospital Dijon France
| | - L. Borradori
- Department of Dermatology Universitätsklinik für Dermatologie Inselspital CH‐3010 Bern Switzerland
| | - C. Prost‐Squarcioni
- Department of Dermatology Avicenne Hospital University Paris 13 Bobigny France
| | - B. Labeille
- Department of Dermatology Saint Etienne University Hospital Saint Etienne France
| | - M.A. Richard
- Aix‐Marseille University UMR 911 INSERM CRO2 ‘Centre de Recherche en Oncologie Biologique et Oncophamacologie’ Department of Dermatology Hôpital Timone Assistance Publique des Hôpitaux de Marseille 264 Rue Saint Pierre 13385 Marseille France
| | - S. Ingen‐Housz‐Oro
- Department of Dermatology Henri Mondor University Hospital AP‐HP Créteil France
| | - E. Houivet
- Department of Biostatistics INSERM U657 Rouen University Hospital University of Rouen Rouen France
| | - V.P. Werth
- Department of Dermatology University of Pennsylvania, and Philadelphia VAMC Philadelphia PA U.S.A
| | - D.F. Murrell
- Department of Dermatology St George Hospital University of NSW Sydney Australia
| | - M. Hertl
- Department of Dermatology Philipps University Marburg Marburg Germany
| | - J. Benichou
- Department of Biostatistics INSERM U657 Rouen University Hospital University of Rouen Rouen France
| | - P. Joly
- Department of Dermatology Rouen University Hospital, and INSERM U905 Institute for Research and Innovation in Biomedicine University of Rouen Rouen France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Hebert V, Boulard C, Houivet E, Duvert Lehembre S, Borradori L, Della Torre R, Feliciani C, Fania L, Zambruno G, Camaioni D, Didona B, Marinovic B, Schmidt E, Schumacher N, Hünefeld C, Schanz S, Johannes Steffen Kern J, Hofmann S, Bouyeure A, Picard-Dahan C, Prost-Squarcioni C, Caux F, Alexandre M, Ingen-Housz-Oro S, Bagot M, Tancrede-Bohin E, Bouaziz J, Franck N, Vabres P, Labeille B, Aleth Richard M, Delaporte E, Dupuy A, D’Incan M, Quereux G, Skowron F, Paul C, Bulai Livideanu C, Beylot-Barry M, Doutre M, Avenel-Audran M, Bedane C, Bernard P, Machet L, Maillard H, Jullien D, Debarbieux S, Sassolas B, Misery L, Abasq C, Dereure O, Lagoutte P, Ferranti V, Werth V, Murrell D, Hertl M, Benichou J, Joly P. Reproductibilité inter-observateur des scores de sévérité du pemphigus ABSIS et PDAI. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
34
|
Houivet E, Hebert V, Boulard C, Vaillant M, Duvert Lehembre S, Borradori L, Della Torre R, Feliciani C, Fania L, Zambruno G, Camaioni D, Didona B, Marinovic B, Schmidt E, Schumacher N, Hünefeld C, Schanz S, Johannes Steffen Kern J, Hofmann S, Bouyeure A, Picard-Dahan C, Prost-Squarcioni C, Caux F, Alexandre M, Ingen-Housz-Oro S, Bagot M, Tancrede-Bohin E, Bouaziz J, Franck N, Vabres P, Labeille B, Aleth Richard M, Delaporte E, Dupuy A, D’Incan M, Quereux G, Skowron F, Paul C, Bulai Livideanu C, Beylot-Barry M, Doutre M, Avenel-Audran M, Bedane C, Bernard P, Machet L, Maillard H, Jullien D, Debarbieux S, Sassolas B, Misery L, Abasq C, Dereure O, Lagoutte P, Ferranti V, Werth V, Murrell D, Hertl M, Benichou J, Joly P. Corrélation entre les scores de sévérité clinique (ABSIS, PDAI, PGA), la qualité de vie (DLQI) et les taux d’Ac anti-desmogléine 1 et 3 dans le suivi du pemphigus. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.048] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
35
|
Joly P, Houivet E, Prost C, Maho-Vaillant M, Picard Dahan C, Duvert Lehembre S, Labeille B, Richard M, Bernard P, Dupuy A, Bouaziz J, Oro S, Chosidow O, Vabres P, Delaporte E, Avenel M, Alexandre M, Caux F, Incan M, Bedane C, Quereux G, Machet L, Dereure O, Skowron F, Franck N, Beylot-Barry M, Doutre M, Beneton N, Debarbieux S, Jullien D, Misery L, Ferranti V, Benichou J, Musette P. Étude randomisée évaluant l’efficacité et la tolérance du rituximab associé à une corticothérapie allégée par rapport à une corticothérapie standard dans le traitement du pemphigus. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
36
|
Loget J, Plée J, Barbe C, Duvert-Lehembre S, Couraud A, Bedane C, Maizières M, Joly P, Bernard P. Évaluation de l’incidence et de la répartition des différentes dermatoses bulleuses auto-immunes dans 3 régions françaises par le registre REGIBUL (2010–2014). Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
37
|
Plee J, Le Jan S, Giustiniani J, Barbe C, Joly P, Bedane C, Vabres P, Truchetet F, Aubin F, Antonicelli F, Bernard P. Étude prospective multicentrique du suivi des concentrations sériques d’IL-17 et d’IL-23 chez les malades atteints de pemphigoïde bulleuse. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.04.040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
38
|
Aubin F, Porcher R, Jeanmougin M, Léonard F, Bedane C, Moreau A, Schmutz JL, Marguery MC, Adamski H, Viguier M. Efficacité et tolérance des immunoglobulines intraveineuses dans l’urticaire solaire et réfractaire : résultats d’une étude de phase II. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
39
|
Lubrano V, Derrey S, Truc G, Mirabel X, Thariat J, Cupissol D, Sassolas B, Combemale P, Modiano P, Bedane C, Dygai-Cochet I, Lamant L, Mourrégot A, Rougé Bugat MÈ, Siegrist S, Tiffet O, Mazeau-Woynar V, Verdoni L, Planchamp F, Leccia MT. [Locoregional treatments of brain metastases for patients with metastatic cutaneous melanoma: French national guidelines]. Neurochirurgie 2014; 60:269-75. [PMID: 25241016 DOI: 10.1016/j.neuchi.2014.05.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2013] [Revised: 05/12/2014] [Accepted: 05/21/2014] [Indexed: 11/22/2022]
Abstract
INTRODUCTION The management of metastatic cutaneous melanoma is changing, marked by innovative therapies. However, their respective use and place in the therapeutic strategy continue to be debated by healthcare professionals. OBJECTIVE The French national cancer institute has led a national clinical practice guideline project since 2008. It has carried out a review of these modalities of treatment and established recommendations. METHODS The clinical practice guidelines development process is based on systematic literature review and critical appraisal by experts. The recommendations are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines are reviewed by independent practitioners in cancer care delivery. RESULTS This article presents the results of bibliographic search, the conclusions of the literature and the recommendations concerning locoregional treatments of brain metastases for patients with metastatic cutaneous melanoma.
Collapse
Affiliation(s)
- V Lubrano
- Service de neurochirurgie, hôpital de Rangueil, CHU de Toulouse, 1, avenue du Professeur-Jean-Poulhès, TSA 50032, 31059 Toulouse, France
| | - S Derrey
- Département de neurochirurgie, hôpital Charles-Nicolle, 1, rue de Germont, 76000 Rouen, France
| | - G Truc
- Département de radiothérapie, centre Georges-François-Leclerc, 1, rue du Professeur-Marion, BP 77980, 21079 Dijon, France
| | - X Mirabel
- Département de radiothérapie-curiethérapie, centre Oscar-Lambret, 3, rue Frédéric-Combemale, BP 307, 59020 Lille, France
| | - J Thariat
- Pôle de radiothérapie, centre Antoine-Lacassagne, 33, avenue de Valombrose, 06189 Nice, France
| | - D Cupissol
- Service d'oncologie médicale, ICM, institut du cancer de Montpellier Val-d'Aurelle, 208, avenue des Apothicaires, parc Euromédecine, 34298 Montpellier, France
| | - B Sassolas
- Service de dermatologie, hôpital Cavale-Blanche, boulevard Tanguy-Prigent, 29609 Brest, France
| | - P Combemale
- Unité onco-dermatologie, centre Léon Bérard, 28, rue Laennec, 69008 Lyon, France
| | - P Modiano
- Service de dermatologie, hôpital Saint-Vincent-de-Paul, boulevard de Belfort, BP 387, 59020 Lille, France
| | - C Bedane
- Service de dermatologie, hôpital Dupuytren, 2, avenue Martin-Luther-King, 87042 Limoges, France
| | - I Dygai-Cochet
- Service de médecine nucléaire, centre Georges-François-Leclerc, 1, rue du Professeur-Marion, BP 77980, 21079 Dijon, France
| | - L Lamant
- Service d'anatomie pathologique, hôpital Purpan, place Baylac, 31059 Toulouse, France
| | - A Mourrégot
- Service de chirurgie oncologique, ICM, institut du cancer de Montpellier Val-d'Aurelle, 208, avenue des Apothicaires, parc Euromédecine, 34298 Montpellier, France
| | - M-È Rougé Bugat
- Cabinet médical, 59, rue de la Providence, 31500 Toulouse, France
| | - S Siegrist
- Cabinet médical, 3, rue Saint-Sigisbert, 57050 le Ban-Saint-Martin, France
| | - O Tiffet
- Service de chirurgie générale et thoracique, centre hospitalier universitaire, 42055 Saint-Étienne, France
| | - V Mazeau-Woynar
- Direction des recommandations et de la qualité de l'expertise, Institut national du cancer, 52, avenue André-Morizet, 92513 Boulogne-Billancourt, France
| | - L Verdoni
- Direction des recommandations et de la qualité de l'expertise, Institut national du cancer, 52, avenue André-Morizet, 92513 Boulogne-Billancourt, France
| | - F Planchamp
- Direction des recommandations et de la qualité de l'expertise, Institut national du cancer, 52, avenue André-Morizet, 92513 Boulogne-Billancourt, France.
| | - M-T Leccia
- Clinique de dermatolo-vénéréologie, photobiologie et allergologie, pôle pluridisciplinaire de médecine, hôpital Michallon, 38043 Grenoble, France
| |
Collapse
|
40
|
Plee J, Le Jan S, Giustiniani J, Joly P, Bedane C, Vabres P, Truchetet F, Aubin F, Antonicelli F, Bernard P. Les profils évolutifs des taux sériques d’IL-17 et d’IL-23 permettent de prédire le risque de rechute de pemphigoïde bulleuse dans la première année de traitement. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
41
|
Prud’homme R, Bedane C, Couture M, Assikar S, Enescu C. Mélanome clitoridien métastatique muté KIT répondant à l’imatinib (Glivec®). Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
42
|
Hurabielle C, Bedane C, Avenel-Audran M, Adamski H, Aubin F, Jeanmougin M, Marguery MC, Peyron JL, Poreaux C, Schmutz JL, Viguier M. Efficacité et tolérance de la ciclosporine dans l’urticaire solaire : étude rétrospective multicentrique. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
43
|
Lebbé C, Chevret S, Jouary T, Dalac S, Guillot B, Dalle S, Arnaud JP, Avril M, Bedane C, Bens G, Beylot-Barry M, Mansart S, Grange F, Meyer N, Machet L, Misery L, Saiag P, Pages C, Battistella M, Mourah S, Dumaz N. Étude multicentrique de phase II non contrôlée évaluant l’intérêt du nilotinib dans le traitement des mélanomes avancés mutés ou amplifiés c-KIT. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
44
|
Cupissol D, Sassolas B, Combemale P, Modiano P, Bedane C, Derrey S, Dygai-Cochet I, Lamant L, Lubrano V, Mirabel X, Mourrégot A, Rougé Bugat ME, Siegrist S, Thariat J, Tiffet O, Truc G, Verdoni L, Mazeau-Woynar V, Planchamp F, Leccia MT. Traitements systémiques de première et de deuxième lignes des patients atteints d’un mélanome cutané métastatique (hors métastase cérébrale) : Recommandations nationales françaises. ONCOLOGIE 2014. [DOI: 10.1007/s10269-013-2360-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
45
|
Leccia MT, Planchamp F, Sassolas B, Combemale P, Modiano P, Bedane C, Cupissol D, Derrey S, Dygai-Cochet I, Lamant L, Lubrano V, Mirabel X, Mourrégot A, Rougé Bugat ME, Siegrist S, Thariat J, Tiffet O, Truc G, Verdoni L, Mazeau-Woynar V. [Management of patients with metastatic cutaneous melanoma: French national guidelines. French National Cancer Institute]. Ann Dermatol Venereol 2013; 141:111-21. [PMID: 24507205 DOI: 10.1016/j.annder.2013.10.055] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2013] [Accepted: 10/25/2013] [Indexed: 11/18/2022]
Abstract
BACKGROUND Recent years have seen the emergence of new molecules for the treatment of patients with metastatic cutaneous melanoma, with significant benefits in terms of survival and the opening of new therapeutic perspectives. In addition, many techniques are currently being developed for locoregional treatment of metastatic sites. Management of metastatic melanoma is thus fast-changing and is marked by innovative therapeutic approaches. However, the availability of these new treatments has prompted debate among healthcare professionals concerning their use and their place in therapeutic strategy. AIMS Since 2008, the French National Cancer Institute (INCa) has been leading a project to define and diffuse national clinical practice guidelines. It has performed a review of these treatment methods, which it aims to circulate, and it is seeking to develop recommendations in order to allow nationwide implementation of innovative approaches while promoting good use thereof. METHODS The clinical practice guidelines development process is based on systematic literature review and critical appraisal by experts within a multidisciplinary working group, with feedback from specialists in cancer care delivery. The recommendations are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines are reviewed by independent practitioners in cancer care delivery. RESULTS This article presents the national recommendations for first- and second-line systemic treatment and for locoregional treatment of metastatic sites in patients presenting metastatic cutaneous melanoma.
Collapse
Affiliation(s)
- M-T Leccia
- Pôle pluridisciplinaire de médecine, clinique de dermatolo-vénéréologie, photobiologie et allergologie, hôpital Michallon, 38043 Grenoble, France
| | - F Planchamp
- Direction des recommandations et de la qualité de l'expertise, Institut national du cancer, 52, avenue André-Morizet, 92513 Boulogne-Billancourt, France.
| | - B Sassolas
- Service de dermatologie, hôpital Cavale Blanche, boulevard Tanguy-Prigent, 29609 Brest, France
| | - P Combemale
- Unité onco-dermatologie, centre Léon-Bérard, 28, rue Laennec, 69008 Lyon, France
| | - P Modiano
- Service de dermatologie, hôpital Saint-Vincent-de-Paul, boulevard de Belfort, BP 387, 59020 Lille, France
| | - C Bedane
- Service de dermatologie, hôpital Dupuytren, 2, avenue Martin-Luther-King, 87042 Limoges, France
| | - D Cupissol
- Service d'oncologie médicale, ICM, institut du cancer de Montpellier Val-d'Aurelle, parc Euromédecine, 208, avenue des Apothicaires, 34298 Montpellier, France
| | - S Derrey
- Département de neurochirurgie, hôpital Charles-Nicolle, 1, rue de Germont, 76000 Rouen, France
| | - I Dygai-Cochet
- Service de médecine nucléaire, centre Georges-François-Leclerc, 1, rue du Professeur-Marion, BP 77980, 21079 Dijon, France
| | - L Lamant
- Service d'anatomie pathologique, hôpital Purpan, place Baylac, 31059 Toulouse, France
| | - V Lubrano
- Service de neurochirurgie, hôpital de Rangueil, 1, avenue du Professeur-Jean-Poulhès, TSA 50032, 31059 Toulouse, France
| | - X Mirabel
- Département de radiothérapie-curiethérapie, centre Oscar-Lambret, 3, rue Frédéric-Combemale, BP 307, 59020 Lille, France
| | - A Mourrégot
- Service de chirurgie oncologique, ICM, institut du cancer de Montpellier Val-d'Aurelle, parc Euromédecine, 208, avenue des Apothicaires, 34298 Montpellier, France
| | - M-E Rougé Bugat
- Cabinet médical, 59, rue de la Providence, 31500 Toulouse, France
| | - S Siegrist
- Cabinet médical, 3, rue Saint-Sigisbert, 57050 Le Ban-Saint-Martin, France
| | - J Thariat
- Pôle de radiothérapie, centre Antoine-Lacassagne, 33, avenue de Valombrose, 06189 Nice, France
| | - O Tiffet
- Service de chirurgie générale et thoracique, centre hospitalier universitaire de Saint-Étienne, 42055 Saint-Étienne, France
| | - G Truc
- Département de radiothérapie, centre Georges-François-Leclerc, 1, rue du Professeur-Marion, BP 77980, 21079 Dijon, France
| | - L Verdoni
- Direction des recommandations et de la qualité de l'expertise, Institut national du cancer, 52, avenue André-Morizet, 92513 Boulogne-Billancourt, France
| | - V Mazeau-Woynar
- Direction des recommandations et de la qualité de l'expertise, Institut national du cancer, 52, avenue André-Morizet, 92513 Boulogne-Billancourt, France
| |
Collapse
|
46
|
Bernard P, Fichel F, Barbe C, Joly P, Bedane C, Vabres P, Truchetet F, Aubin F, Michel C, Jegou J, Grange F, Antonicelli F. Facteurs cliniques et immunologiques associés aux rechutes de pemphigoïde bulleuse dans la première année de traitement : étude multicentrique et prospective. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
47
|
Commin M, Prost C, Picard-Dahan C, Duvert-Lehembre S, Labeille B, Paul C, Richard M, Dalac S, Bernard P, Dupuy A, Bouaziz J, Oro SIH, Avenel M, Sassolas B, Alexandre M, Caux F, D’Incan M, Delaporte E, Bedane C, Quereux G, Machet L, Vabres P, Dereure O, Skowron F, Franck N, Barry MB, Maillard H, Debardieux S, Jullien D, Misery L, Ferranti V, Joly P. Analyse intermédiaire de l’efficacité du rituximab comme traitement de première intention du pemphigus. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
48
|
Boulard C, Bouyeure A, Houivet E, Borradori L, Huenefeld C, Schmidt E, Marinovic B, Zambruno G, Feliciani C, Prost C, Picard-Dahan C, Duvert Lehembre S, Labeille B, Paul C, Richard M, Dalac S, Bernard P, Dupuy A, Caux F, Bouaziz J, Oro S, Avenel-Audran M, Misery L, Sassolas B, Alexandre M, D’Incan M, Delaporte E, Bedane C, Quereux G, Machet L, Vabre P, Dereure O, Skowron F, Franck N, Beylot-Barry M, Beneton Benhard N, Debarbieux S, Jullien D, Benichou J, Ferranti V, Murrell D, Hertl M, Joly P. Qualité de vie chez les patients atteints de pemphigus : corrélation avec le type et la sévérité du pemphigus. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
49
|
Bertolotti A, Pham-Ledard AL, Vergier B, Parrens M, Bedane C, Beylot-Barry M. Lymphomatoid papulosis type D: an aggressive histology for an indolent disease. Br J Dermatol 2013; 169:1157-9. [DOI: 10.1111/bjd.12463] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- A. Bertolotti
- Department of Dermatology; CHU Bordeaux; University of Bordeaux; Bordeaux France
| | - A.-L. Pham-Ledard
- Department of Dermatology; CHU Bordeaux; University of Bordeaux; Bordeaux France
| | - B. Vergier
- Department of Pathology; CHU Bordeaux; University of Bordeaux; Bordeaux France
| | - M. Parrens
- Department of Pathology; CHU Bordeaux; University of Bordeaux; Bordeaux France
| | - C. Bedane
- Department of Dermatology; CHU Limoges; Limoges France
| | - M. Beylot-Barry
- Department of Dermatology; CHU Bordeaux; University of Bordeaux; Bordeaux France
| |
Collapse
|
50
|
Bedane C. Les photoprotecteurs externes et les antioxydants sont-ils néfastes pour la santé ? Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.01.375] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|